Seer, Inc.
NASDAQ:SEERBiotechnology
+$0.01 today
- Market cap
- $80.37M
- Beta
- 1.59
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.26
Volume 0.23M
Average 0.32M
Income Statement
Follow revenue through to earnings.
Revenue
$16.12M
FY 2025 · Annual
+15.6% YoYOperating Income
-$78.45M
FY 2025 · Annual
Net Income
-$73.60M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.39M | 14.69M | 15.18M | 13.95M | 16.12M |
| Cost of Revenue | 6.77M | 14.3M | 13.73M | 7.12M | 14.22M |
| Gross Profit | (374K) | 384K | 1.45M | 6.83M | 1.9M |
| Gross Margin | -5.8% | 2.6% | 9.5% | 49.0% | 11.8% |
| Research & Development | 29.12M | 45.8M | 47.44M | 50.59M | 37.77M |
| Selling, General & Admin | 42.2M | 52.63M | 58.95M | 56.57M | 42.58M |
| Operating Expenses | 71.32M | 98.43M | 106.39M | 106.93M | 80.35M |
| Depreciation & Amortization | 3.56M | 5.9M | 5.58M | 6.18M | 6.1M |
| EBITDA | (67.61M) | (87.07M) | (80.7M) | (80.33M) | (67.3M) |
| EBITDA Margin | -1057.3% | -592.9% | -531.5% | -575.9% | -417.5% |
| Operating Income | (71.7M) | (98.04M) | (104.94M) | (100.1M) | (78.45M) |
| Operating Margin | -1121.3% | -667.6% | -691.2% | -717.7% | -486.7% |
| Interest Income | 326K | 4.6M | 17.76M | 16.67M | 11.52M |
| Interest Expense | 22K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 527K | 5.08M | 18.67M | 13.6M | 5.05M |
| Income Before Tax | (71.17M) | (92.97M) | (86.28M) | (86.5M) | (73.4M) |
| Pre-Tax Margin | -1113.1% | -633.1% | -568.3% | -620.2% | -455.4% |
| Income Tax Expense | 0 | 0 | 0 | 98K | 201K |
| Net Income | (71.17M) | (92.97M) | (86.28M) | (86.6M) | (73.6M) |
| Net Margin | -1113.1% | -633.1% | -568.3% | -620.9% | -456.6% |
| EPS (Basic) | (1.13) | (1.42) | (1.35) | (1.39) | (1.28) |
| EPS (Diluted) | (1.13) | (1.42) | (1.35) | (1.39) | (1.28) |
| 60.86M | 62.43M | 63.85M | 62.35M | 57.45M | |
| 60.86M | 62.43M | 63.85M | 62.35M | 57.45M |
SEER Earnings Waterfall · TTM
NASDAQ:SEER · Revenue to Net Income
Key Ratios
Analysis
$15.0M of revenue converted into -$70.5M of net income for the selected period. Gross margin is 47.2% and net margin is -479.4%, showing how much revenue survives after costs and taxes. EPS is $-1.24, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
Market cap
$10.89B
Pharvaris N.V.
NASDAQ:PHVS
Market cap
$2.34B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
Market cap
$1.69B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Market cap
$1.36B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Market cap
$814.71M
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
Market cap
$800.67M
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Market cap
$667.39M
Sana Biotechnology, Inc.
NASDAQ:SANA
Market cap
$605.26M
Shattuck Labs, Inc.
NASDAQ:STTK
Market cap
$473.57M
C4 Therapeutics, Inc.
NASDAQ:CCCC
Market cap
$362.43M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Market cap
$351.57M
PepGen Inc.
NASDAQ:PEPG
Market cap
$301.98M
Quantum-Si incorporated
NASDAQ:QSI
Market cap
$229.78M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Market cap
$172.64M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Market cap
$124.12M
Molecular Partners AG
NASDAQ:MOLN
Market cap
$112.71M
Nkarta, Inc.
NASDAQ:NKTX
Market cap
$85.23M
MediciNova, Inc.
NASDAQ:MNOV
Market cap
$68.66M
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| SC 13D | SC 13D filing | Nov 2, 2026 | |
| 8-K | Current report | Oct 29, 2026 |
How much revenue does SEER generate?
Seer, Inc. (SEER) reported $16.12M of revenue in fiscal 2025.
Is SEER profitable?
Seer, Inc. (SEER) reported -$73.60M of net income, with a net margin of -456.6%.
Continue the stock analysis
Jump to another research area for this company.